2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-128510
    Colterol 18866-78-9 98%
    Colterol is the agonist for adrenergic receptor, and exhibits good affinity to β1-adrenoreceptor (heart) and β2-adrenoreceptor (lung) with IC50 of 645 nM and 147 nM. Colterol exhibits potential as a bronchodilator.
    Colterol
  • HY-129206
    Locicortolone 65049-45-8 98%
    Locicortolone (RU-24476) is a synthetic steroid compound. Locicortolone inhibits Angiotensin I (AI) induced pressor response. Locicortolone can be used in antihypertensive studies.
    Locicortolone
  • HY-129258
    Lycoctonine 26000-17-9 98%
    Lycoctonine is a diterpene alkaloid. Lycoctonine interacts the sodium channel, affects the heart and central nervous system, exhibits analgesic, anti-inflammatory, anti-epileptic and cardiovascular activities.
    Lycoctonine
  • HY-129445
    SG-209 83440-03-3 98%
    SG-209 is a Nicorandil (HY-B0341) derivative that produces relaxation through potassium channel activation, while this action contributes to the vasodilating action of Nicorandil (HY-B0341) at higher concentrations. SG-209 dilates tracheal smooth muscle and increases tracheal blood flow in anesthetized dogs.
    SG-209
  • HY-129474
    MP 518 122432-93-3 98%
    MP 518 is a PDE inhibitor with antihypertensive properties. MP 518 can inhibit cAMP degradation, causing an increase in ICa, and can also antagonize β-adrenergic stimulation, exerting vasodilation.
    MP 518
  • HY-129607
    A-65317 122224-84-4 98%
    A-65317 is a primate-selective renin dipeptide inhibitor (IC50 of 0.37 nM) with long hypotensive response.
    A-65317
  • HY-129648
    AC-7954 free base 734528-95-1 98%
    AC-7954 free base is a selective nonpeptidic urotensin receptor agonist (EC50: 300 nM at the human UII receptor).
    AC-7954 free base
  • HY-129699
    RH01617 302333-18-2 98%
    RH01617 is a Kv1.5. potassium channel and MMP-13 inhibitor. RH01617 can be used for research of atrial fibrillation.
    RH01617
  • HY-129709
    DAC 5945 124065-13-0 98%
    DAC 5945 is a potent muscarinic antagonist in the airways than in the heart, with pKi values of 8.3 and 7.52 for M1 and M2, respectively.
    DAC 5945
  • HY-129733
    LND 623 90520-42-6 98%
    LND 623 is an inotropic aminosteroid with positive inotropic properties. LND 623 inhibits Na+/K+ ATPase activity. The LD50 of LND 623 infused i.v. is around 45 mg/kg, a value ten times higher than the LD50 for Ouabain (HY-B1457).
    LND 623
  • HY-130448
    8-iso Prostaglandin F1β 26771-95-9 98%
    8-iso Prostaglandin F1β is an isoprostane, that exhibits vasoconstrictive effect in neonatal porcine pulmonary arteries, pulmonary veins, and mesenteric arteries. 8-iso Prostaglandin F1β targets TXA2 receptor and exhibits the blood vessel contractile efficacy under the influence of tyrosine kinase and Rho kinase.
    8-iso Prostaglandin F1β
  • HY-130456
    AHR 10718 96436-73-6 98%
    AHR 10718 is an antiarrhythmic agent that suppresses cardiac arrhythmias induced by digitalis intoxication and myocardial infarction in the intact dog. AHR 10718 also depresses membrane responsiveness and conduction, shortens the effective refractory period of specialized conducting fibers less than action potential duration.
    AHR 10718
  • HY-130581
    Lipid X 86559-73-1 98%
    Lipid X is a 2,3-diacylglucosamine-1-phosphate that serves as the monosaccharide precursor of lipid A, possessing both LPS antagonist and weak agonist activities. Lipid X exerts protective effects by inhibiting tumor necrosis factor production, monocyte procoagulant activity, and neutrophil priming. Lipid X may induce transient pulmonary hypertension, neutropenia, and mild pyrogenic effects in laboratory animals. Lipid X has low toxicity and no in vitro antibacterial activity, but it significantly reduces mortality following Gram-negative bacterial infection and endotoxin exposure. Lipid X tends to accumulate in liver tissue, binds to circulating cellular components, and can be converted to lipid Y through transesterification. Lipid X can be used in research on Gram-negative bacterial sepsis, endotoxemia, and associated pulmonary hypertension.
    Lipid X
  • HY-13104R
    MRS 2578 (Standard) 711019-86-2
    MRS 2578 (Standard) is the analytical standard of MRS 2578. This product is intended for research and analytical applications. MRS 2578 is a selective and potent P2Y6 receptor antagonist with IC50s of 37 nM (human) and 98 nM (rat). MRS 2578 exhibits insignificant activity at P2Y1, P2Y2, P2Y4, and P2Y11 receptors.
    MRS 2578 (Standard)
  • HY-131473
    Desmethyl thiosildenafil 479073-86-4 98%
    Desmethyl thiosildenafil is a phosphodiesterase type 5 (PDE5) inhibitor[1].
    Desmethyl thiosildenafil
  • HY-131728
    GPR35 agonist 3 123021-85-2 98.32%
    GPR35 agonist 3 is a synthetic GPR35 agonist with an EC50value of 1.4 μM. GPR35 agonist 3 can be used for the research of various diseases, such as gastric cancer, type 2 diabetes, cardiovascular diseases, immune system and peripheral nervous system.
    GPR35 agonist 3
  • HY-131776
    2-Chloro-ADP 16506-88-0 98%
    2-Chloro-ADP (2-Chloroadenosine 5′-diphosphate) sis a Adenosine 5'-diphosphate (ADP; HY-W010918) derivative that induces human platelet aggregation and inhibits stimulated adenylate cyclase. 2-Chloro-ADP inhibits mortalin nucleotide-binding domain (NBD) with a Ki of 45.05 μM.
    2-Chloro-ADP
  • HY-132002
    Dimethylsildenafil 1416130-63-6 98%
    Dimethylsildenafil is a derivative of Sildenafil (HY-15025). Sildenafil is a potent phosphodiesterase type 5 (PDE5) inhibitor with an IC50 of 5.22 nM.
    Dimethylsildenafil
  • HY-13209R
    Ambrisentan (Standard) 177036-94-1 98%
    Ambrisentan (Standard) is the analytical standard of Ambrisentan. This product is intended for research and analytical applications. Ambrisentan is a selective ET type A receptor (ETAR) antagonist.
    Ambrisentan (Standard)
  • HY-13327R
    Evacetrapib (Standard) 1186486-62-3 98%
    Evacetrapib (Standard) is the analytical standard of Evacetrapib. This product is intended for research and analytical applications. Evacetrapib is a potent and selective of CETP inhibitor, which inhibits human recombinant CETP protein (IC50 5.5 nM) and CETP activity in human plasma (IC50 36 nM) in vitro.
    Evacetrapib (Standard)
Cat. No. Product Name / Synonyms Application Reactivity